J
Johan Lennartsson
Researcher at Uppsala University
Publications - 85
Citations - 4679
Johan Lennartsson is an academic researcher from Uppsala University. The author has contributed to research in topics: Platelet-derived growth factor receptor & Phosphorylation. The author has an hindex of 33, co-authored 78 publications receiving 4124 citations. Previous affiliations of Johan Lennartsson include Science for Life Laboratory & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
TL;DR: The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clinically used inhibitor imatinib mesylate.
Journal ArticleDOI
A cis -acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse
Gerli Pielberg,Anna Golovko,Elisabeth Sundström,Ino Curik,Johan Lennartsson,Monika Seltenhammer,Thomas Druml,Matthew M. Binns,Carolyn Fitzsimmons,Gabriella Lindgren,K. Sandberg,Roswitha Baumung,Monika Vetterlein,Sara Strömberg,Manfred Grabherr,Claire M. Wade,Claire M. Wade,Kerstin Lindblad-Toh,Kerstin Lindblad-Toh,Fredrik Pontén,Carl-Henrik Heldin,Johann Sölkner,Leif Andersson,Leif Andersson +23 more
TL;DR: It is shown that the Gray phenotype is caused by a 4.6-kb duplication in intron 6 of STX17 (syntaxin-17) that constitutes a cis-acting regulatory mutation that is overexpressed in melanomas from Gray horses.
Journal ArticleDOI
Normal and oncogenic forms of the receptor tyrosine kinase kit.
TL;DR: The objective of this review is to summarize what is known about normal and oncogenic forms of Kit and to place particular emphasis on recent developments in understanding the mechanisms of action of normal and activated forms of this RTK and its association with human disease.
Journal ArticleDOI
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
Fan Zhang,Zhongshu Tang,Xu Hou,Johan Lennartsson,Yang Li,Alexander W. Koch,Pierre Scotney,Chunsik Lee,Pachiappan Arjunan,Lijin Dong,Anil Kumar,Tuomas T. Rissanen,Bin Wang,Nobuo Nagai,Pierre Fons,Robert N. Fariss,Yongqing Zhang,Eric F. Wawrousek,Ginger Tansey,James Raber,Guo-Hua Fong,Hao Ding,David A. Greenberg,Kevin G. Becker,Jean-Marc Herbert,Andrew D. Nash,Seppo Ylä-Herttuala,Yihai Cao,Ryan J. Watts,Xuri Li +29 more
TL;DR: This work indicates that the function of VEGF-B in the vascular system is to act as a “survival,” rather than an “angiogenic” factor and that VEGf-B inhibition may offer new therapeutic opportunities to treat neovascular diseases.
Journal ArticleDOI
Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction
Johan Lennartsson,Peter Blume-Jensen,Peter Blume-Jensen,Monica Hermanson,Emma Pontén,Monika Carlberg,Lars Rönnstrand +6 more
TL;DR: Data show that Ras/MAP kinase activation and c-fos induction by Kit/SCFR are mediated by members of the Src family kinases, however, the mitogenic response is only to a minor extent dependent on Src kinase activity.